RTTNews汇总美股生物科技股当日涨幅榜，未披露新的单名可交易催化

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Blockchain
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Corp. News
Market News
Health News
Entertainment News
Music News
TODAY'S TOP STORIES
By
Prabha Kurup
✉
|
Published:
7/28/2026 10:44 PM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp rebound after a recent selloff, among others.
Read on…
TRIB Soars
Trinity Biotech plc (
TRIB
), a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, was one of the top gainers on Tuesday.
Earlier this month, the company announced clinical study results showing that its next-generation CGM+ wearable biosensor platform successfully demonstrated a purpose-built capability to detect nocturnal compression-induced false low glucose events, addressing a common limitation of conventional continuous glucose monitoring (CGM) systems through its differentiated
technology
.
Compression-related false low glucose alarms are a common source of inaccurate CGM alerts.
As CGM+ enters the final stages of development, the company plans to incorporate its nocturnal compression low detection capability into the platform ahead of pivotal clinical trials and subsequent regulatory submission.
A one-for-thirty reverse ADS split was implemented on July 24, 2026, to enable the company to regain compliance with the $1.00 Nasdaq minimum bid price requirement.
TRIB closed Tuesday's trading at $12.45, up 36.07%.
OPK On Watch
OPKO Health Inc. (
OPK
) jumped more than 33%, following its financial results for the second quarter of 2026 and pipeline progress.
Consolidated total revenues for the second quarter of 2026 were $163.5 million compared with $156.8 million for the 2025 period.
However, the company issued softer guidance for the third quarter, forecasting revenue of $131 million to $142 million, compared with $151.7 million in the year-ago quarter. For full-year 2026, OPKO expects total revenue of $560 million to $580 million, below $606.9 million reported in 2025.
On the pipeline front, OPKO highlighted continued progress across multiple early-stage programs.
Enrollment is ongoing in the Phase 1 trial of MDX2003 for B-cell lymphomas, which is evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The Phase 1 trial of MDX2301 for the prevention of COVID-19 is also advancing, with enrollment expected to be completed in the third quarter of 2026 and initial data anticipated in late 2026 or early 2027.
Meanwhile, the Phase 1 study of MDX2001, targeting solid tumors, continues to enroll participants, with initial safety, tolerability, pharmacokinetic, and immune data expected in the first half of 2027.
The company also noted that its Phase 1/2a clinical study of OPK-88006 in healthy volunteers and presumed MASH participants remains underway.
OPK closed Tuesday's trading at $1.65, up 33.06%.
KNSA Hits All-time High
Kiniksa Pharmaceuticals International plc (
KNSA
) touched an all-time high of $81.97 during intraday trading on Tuesday after reporting strong second-quarter 2026 financial results and raising its full-year revenue outlook.
The company has been witnessing expanding sales of its lead drug Arcalyst, the first and only FDA-approved therapy for recurrent pericarditis, a painful and debilitating auto-inflammatory cardiovascular disease.
Arcalyst generated $243.6 million in net product revenue in Q2, 2026, representing approximately 55% year-over-year growth. Reflecting the drug's sustained commercial momentum, Kiniksa increased its full-year 2026 net product revenue guidance to $980 million to $995 million, up from its prior forecast of $930 million to $945 million, and well above the $677.6 million reported in 2025.
KNSA closed Tuesday's trading at $79.44, up 25.03%.
MPLT on the Mend?
MapLight Therapeutics Inc. (
MPLT
), which plunged nearly 73% on Monday after reporting mixed Phase 2 schizophrenia trial results, rebounded sharply on Tuesday to rank among the session's top gainers.
On Monday, the company had announced that its Phase 2 study met the primary endpoint with the 210/3 mg twice-daily (BID) dose of ML-007C-MA, demonstrating a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score versus placebo at Week 5. However, the 330/6 mg once-daily (QD) dose, which provides lower overall daily drug exposure than the BID dosing, showed only a numerical improvement over placebo and failed to achieve statistical significance on the primary endpoint.
The mixed trial results triggered a steep selloff, sending the stock to an intraday low of $9.90 on Monday. Selling pressure briefly persisted on Tuesday, with shares touching an all-time low of $9.10 before staging a strong rebound to close the day up more than 24%.
The company plans to engage with the FDA at an End-of-Phase 2 (EOP2) meeting to discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial.
ML-007C-MA is also being evaluated as a potential treatment for Alzheimer's disease psychosis.
A Phase 2 clinical trial of ML-007C-MA for the treatment of Alzheimer's disease psychosis, dubbed VISTA, is underway. The VISTA trial is designed to enroll approximately 300 participants, and topline results are expected in the second half of 2027.
MPLT closed Tuesday's trading at $12.31, up 24.28%.
PMN Rallies as Early PMN310 Data Sparks Investor Optimism
Shares of ProMIS Neurosciences Inc. (
PMN
) jumped more than 23% on Tuesday after the company reported positive blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b clinical trial of PMN310 in patients with Alzheimer's disease.
In the blinded interim analysis of 136 Alzheimer's disease patients, PMN310 demonstrated a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) reported as of the data cutoff.
The company expects to report topline 12-month results from the trial in the first quarter of 2027.
PMN closed Tuesday's trading at $14.52, up 23.89%.
PRLD Moves Up on a Quiet Day
Prelude Therapeutics Inc. (
PRLD
), a clinical-stage precision oncology company, jumped more than 19% on Tuesday on no specific news.
The company's lead pipeline candidate, PRT12396, is currently being evaluated in a Phase 1 clinical trial in patients with polycythemia vera (PV) and myelofibrosis (MF).
Prelude is also advancing PRT13722, with an Investigational New Drug (IND) application submission expected by mid-2026 and a Phase 1 study initiation in ER-positive breast cancer anticipated in the second half of 2026.
PRLD closed Tuesday's trading at $4.64, up 19.28%.
Did you know?
Some people are allergic to water.
Aquagenic urticaria is an extremely rare skin condition in which contact with water can trigger the sudden appearance of hives, regardless of the water's temperature or source. Within about 30 minutes of exposure, affected individuals may develop hives, most commonly on the arms, legs, and trunk, while the palms are usually unaffected. The symptoms typically resolve within 30 to 60 minutes after removing contact with water. (Source: BMJ Journal)
For comments and feedback contact: editorial@rttnews.com
Business News
Biotech Stocks Facing FDA Decision In July 2026
Biotech Stocks Facing FDA Decision In June 2026
Biotech Stocks Facing FDA Decision In May 2026
Next Story
Latest Updates on Middle East War
U.S. Dollar Slips As Easing Crude Oil Prices Lower Fed Rate Hike Expectations
July 28, 2026 17:00 ET
Canadian Stocks Advance As Tech Sector Gains Offset Materials, Energy Losses
July 28, 2026 16:30 ET
Crude Oil Plummets As Supply Disruption Concerns Continue To Diminish
July 28, 2026 14:35 ET
Gold Tumbles Amid Reduced Safe-Haven Demand As U.S.-Iran Continue To Pause Attacks
July 28, 2026 13:36 ET
U.S. Dollar Ticks Higher As Easing Middle East Tensions Lowers Fed Rate Hike Expectations
July 27, 2026 17:00 ET
View More
Global Economics Weekly Update - July 20 – July 24, 2026
July 25, 2026 02:46 ET
The latest policy decision from the European Central Bank dominated the scene this week that was relatively slow for economics news flow. In the U.S., main highlights were the weekly initial jobless claims and new home sales data. In Europe, the ECB rate decision and the latest inflation figures from the U.K. drew attention. In Asia, results of a private sector survey from India were in focus.
View More Videos
RELATED NEWS
MapLight Reports Results From Phase 2 ZEPHYR Trial Of ML-007C-MA; Stock Down More Than 60%
MapLight Reports Mixed Results From Phase 2 ZEPHYR Schizophrenia Trial; Shares Fall
Can ZEPHYR Schizophrenia Trial Data Light Up MapLight?
MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents
Latest Updates on COVID-19
KFF Poll Finds AI Health Chatbot Users More Likely To Believe Vaccine Myths
July 01, 2026 14:27 ET
Editor's Pick
Most Read
Most Emailed
Boeing Q4 Net Loss Narrows, Revenues Rise 8%
July 28, 2026 08:03 ET
Coca-Cola Boosts FY26 Outlook - Update
July 28, 2026 07:24 ET
UPS Lifts FY26 Outlook, Despite Weak Q2 Profit
July 28, 2026 07:09 ET
Philips Stock Drops On Weak Q2 Orders, Despite Profit Growth, Positive Outlook
July 28, 2026 06:01 ET
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
July 27, 2026 04:19 ET
Verizon Lifts FY26 View Despite Weak Q2, Expands Buyback To Up To $4.5 Bln; Shares Up
July 24, 2026 10:21 ET
EU Commission Flags TikTok's Minor Account Safety Gaps
July 24, 2026 09:56 ET
Volkswagen Cuts FY26 Revenue View After Weak Q2 Profit, Volume
July 24, 2026 05:33 ET
T-Mobile US Q2 Profit Edges Up, Net Additions Drop, Backs FY26 View; Stock Down
July 23, 2026 09:43 ET
Ecolab Raises 2026 Earnings Guidance
July 28, 2026 08:33 ET
WSP Raises Arcadis Acquisition Offer To €51.50 After Initial Rejection
July 24, 2026 11:50 ET
Amapá Minerals Reveals Pricing Of IPO Of 127.27 Mln Common Shares At $1.10/Shr
July 24, 2026 01:42 ET
Union Pacific Signs MoU With CN Supporting Proposed Norfolk Southern Merger
July 23, 2026 01:19 ET
Expand Energy To Buy Twin Eagle For $1.25 Bln
July 27, 2026 07:49 ET
Carpenter Technology CEO Brian Malloy Passes Away; Tony Thene Named CEO
July 27, 2026 08:18 ET
Eligible Amazon Prime Members Have Until July 27 To Claim Up To $51 In FTC Settlement
July 24, 2026 17:15 ET
ATOSS H1 Profit Rises On Higher Revenue; Maintains FY26, FY27 Forecast
July 24, 2026 02:41 ET
ProStar Holdings Appoints Michael Wolff As CEO, Succeeding Founder Page Tucker; Shares Down
July 27, 2026 08:34 ET
Safety Insurance To Be Acquired By Mapfre In $1.54 Bln All-Cash Deal
July 23, 2026 17:11 ET
West Bancorporation Inc. Reveals Rise In Q2 Profit
July 23, 2026 09:02 ET
Westports Holdings Berhad Bottom Line Advances In Q2
July 23, 2026 00:56 ET
NVR Inc. Bottom Line Declines In Q2
July 23, 2026 09:05 ET
SFS Group AG H1 Income Rises
July 23, 2026 00:58 ET
ACNB Corporation Reports Increase In Q2 Bottom Line
July 23, 2026 09:07 ET
Cembra Money Bank AG Announces Increase In H1 Income
July 23, 2026 01:02 ET
Mapletree Industrial Trust Profit Drops In Q1
July 23, 2026 09:11 ET
Givaudan H1 Profit, Sales Down; Backs LFL Sales Growth View Ahead
July 23, 2026 01:03 ET
Kearny Financial Corp. Q4 Sales Increase
July 23, 2026 09:16 ET
Pihlajalinna Oyj Bottom Line Falls In Q2
July 23, 2026 01:07 ET
Mapletree Industrial Trust Q1 Profit Drops
July 23, 2026 09:23 ET
LS ELECTRIC Q2 Operating Income Rises
July 23, 2026 01:17 ET
Editors Pick
Loading...
Copyright © 2026 RTTNews. All rights reserved.
By using this site, you agree to the
Terms of Service
About Us
Privacy
Sitemap